Sage Therapeutics Gets Fast-Track Designation for Huntington's Disease Treatment

By Dave Sebastian

Sage Therapeutics Inc. said it has gotten a fast-track designation from the Food and Drug Administration for its Sage-718 drug candidate to be developed as potential treatment for Huntington's disease.

The fast track is a process for facilitating the development and review of new treatments for severe conditions.

Sage said it expects to start a Phase 2 trial with the drug candidate in early to moderate Huntington's disease in late 2021.

Huntington's disease is a rare, inherited neurodegenerative disease, Sage said. As many as 30,000 adults are diagnosed with the disease in the U.S. each year, the company said.

Write to Dave Sebastian at [e-mail]

(END) Dow Jones Newswires

09-15-21 0659ET